Hip resurfacing implant offers lower revision, complication rates for hip arthritis

Su EP. J Arthroplasty. 2014. doi:10.1016/j.arth.2014.03.021.

Use of hip resurfacing arthroplasty for the treatment of hip arthritis in younger patients demonstrated a lower rate of revision and complications at short-term follow up, according to study results.

In an ongoing, prospective, multicenter cohort study, researchers have aimed to assess the safety and efficacy of a hip resurfacing implant in 265 patients. The researchers used Harris Hip Score, Euroqol-EQ-5D (EQ-5D) and range of motion to assess patients at the preoperative visit and at 6 weeks, 3 months, 1 year and annually thereafter. Additionally, biplanar radiographs were taken preoperatively, at 1 month and 1 year postoperatively, and annually thereafter.

Study results showed an improvement in Harris Hip Scores from a preoperative average of 56.8 to 96.9 at 2 years and 97 at 4 years, as well as a significant increase in EQ-5D score from 70.6 preoperatively to 88.5 at 1 year and 87.6 at 2 years, according to the researchers.

With regard to implant survivorship at 5 years postoperatively, women had a Kaplan-Meier survival of 94.7% and men had a 98.6% survivorship. Only seven revisions have been recorded to date, according to the researchers.

At 1 year, 267 hips had metal ion testing, at which time the researchers found a median whole blood cobalt level of 1.51 ppb and a median whole blood chromium level of 1.7 ppb. These results increased at 4 years with 112 hips at a 1.56 ppb median whole blood cobalt level and a 1.8 ppb median whole blood chromium level.

Disclosure: See the study for a full list of all authors’ relevant financial disclosures.


Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button